 For Arm 3, subjects who are successfully screened will be randomly assigned by a computer to one of 6 groups. All subjects will receive a GnRH agonist goserelin acetate Zoladex; AstraZeneca, Wilmington, DE 3.6 mg sc every 4 weeks for 16 weeks. Subjects in Group 1 will receive goserelin acetate and placebo for Androgel. Subjects in Groups 2-5 will receive varying doses of Androgel. Subjects in Group 6 will receive double placebo e.g. placebo Zoladex and placebo Androgel. Subjects will be blinded with respect to group assignment. Dietary calcium intake will be assessed by a research dietitian and adjustments made through diet or supplements so that calcium intake is between 1000 and 1200 mgday. 